Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

What markers track mucosal healing?

Mucosal healing is assessed endoscopically, but repeated colonoscopy is poorly tolerated, so research has turned to fecal and serum markers — calprotectin, CHI3L1, MMP-9, NGAL — and to tissue-level readouts of epithelial

peptides-pro Editorial

Mucosal healing is the endoscopic resolution of visible ulceration and inflammation at the intestinal surface, and it is currently treated in ulcerative colitis (UC) research as the best available therapeutic endpoint [3]. Because its routine use is limited by the low acceptability of repeated colonoscopies, a substantial part of the field's effort has gone into identifying non-invasive markers that track the same underlying process [3]. The candidate markers that recur across the evidence are fecal calprotectin, fecal chitinase 3-like 1 (CHI3L1), fecal matrix metalloprotease type 9 (MMP-9), the serum combination of neutrophil gelatinase B-complex associated lipocalin (NGAL) with MMP-9, and serum CHI3L1 [3].

The mechanistic work in this area centres on epithelial barrier repair and the inflammatory signalling that opposes it, with the NAD-dependent deacetylase sirtuin-1 (SIRT1)/signal transducer and activator of transcription 3 (STAT3) pathway appearing as one regulatory axis in a murine colitis model [1].

Research Studies

Fecal and serum biomarkers and endoscopic activity in ulcerative colitis

Fecal calprotectin has shown a very good negative predictive value for eliminating an IBD diagnosis, good correlation with endoscopic activity, and good ability to predict relapse [3]. Several groups, including the investigators behind the biomarker-variation study, have reported that fecal CHI3L1, fecal MMP-9, the serum NGAL-MMP9 combination, and serum CHI3L1 may perform better than calprotectin in some comparisons [3]. That study was designed to measure variation in serum and fecal biomarkers after treatment as a way of predicting mucosal healing in UC patients, on the premise that a validated marker panel would reduce reliance on repeat colonoscopy [3].

MarkerSpecimenReported performance
CalprotectinFecalVery good negative predictive value for excluding IBD; good correlation with endoscopic activity; predicts relapse [3]
CHI3L1Fecal and serumReported by several teams as potentially better than calprotectin [3]
MMP-9FecalReported as potentially better than calprotectin [3]
NGAL-MMP9SerumReported as potentially better than calprotectin [3]

GHK-Cu and the SIRT1/STAT3 pathway in DSS-induced murine colitis

Glycyl-l-histidyl-l-lysine-copper (GHK-Cu) has known anti-inflammatory properties, but its mechanisms in UC were undefined before this work [1]. The study evaluated GHK-Cu in a dextran sulfate sodium (DSS)-induced murine model of UC in BALB/c mice, with emphasis on its regulatory effects on the SIRT1/STAT3 signalling pathway [1]. The framing premise is that UC is a chronic inflammatory bowel disease characterised by mucosal damage and impaired epithelial barrier function, which is the same lesion that mucosal healing describes the resolution of [1]. This is animal-model evidence; it does not establish marker behaviour in humans.

Probiotics and trace elements as adjuncts to infliximab in UC patients

An interventional observational study is evaluating lactobacillus probiotics or trace elements added to infliximab for maintaining remission in UC patients, and comparing the two adjuncts against each other [2]. It is an open-label, parallel, prospective design conducted in the outpatient IBD and gastroenterology clinic of the National Hepatology and Tropical Medicine Research Institute (NHTMRI) in Cairo, Egypt, with patients randomly allocated to three groups; Group I receives 20 billion colony forming units [2]. Remission maintenance is the outcome of interest rather than a specific mucosal-healing marker, so this trial speaks to the treatment side of the question rather than to marker validation [2].

Non-healing versus iatrogenic colonic ulcers: gene expression and mitochondrial function

A separate study compares non-healing colonic ulcers in IBD patients with iatrogenic colonic ulcers at biopsy sites in healthy controls and in patients with rheumatoid or psoriatic arthritis [4]. The design uses a "biopsy of the biopsy" approach, with biopsies taken at baseline and again at follow-up, to reveal patterns in gene expression and mitochondrial function during ulcer healing [4]. The comparison is informative because it separates ulcers that fail to heal in IBD from ulcers that heal normally after a controlled iatrogenic injury [4].

Malnutrition enteropathy and epithelial regeneration in severe acute malnutrition

The TAME study evaluates four approaches against standard care for malnutrition enteropathy in children with severe acute malnutrition [5]. In this population, a high pathogen burden damages the intestinal mucosa, which exacerbates nutritional impairment and increases susceptibility to infection and impaired epithelial regeneration; enteropathy is characterised by multiple epithelial breaches, microbial translocation from the gut lumen to the systemic circulation, and systemic inflammation [5]. Four interventions — colostrum, N-acetyl glucosamine, teduglutide, and budesonide — are given for 14 days [5]. This is a paediatric clinical population, and the readouts are enteropathy-related rather than the UC marker panel described above [5].

Zinc L-carnosine and epithelial repair in oral mucosa

A systematic review and meta-analysis examined the protective and healing effects of zinc L-carnosine (ZnC) on the oral mucosa, where mucosal injury is a frequent complication in oncologic and surgical settings [6]. ZnC is described as a cytoprotective compound with anti-inflammatory, antioxidant, and epithelial reparative properties [6]. The tissue here is oral rather than intestinal, so the findings are relevant to the general question of what tracks epithelial repair but are not a direct statement about colonic mucosal healing [6].

What the marker evidence does and does not establish

Across the sources above, the strongest marker performance claims are for calprotectin as a rule-out and relapse predictor, with CHI3L1, MMP-9, and NGAL-MMP9 proposed as improvements on it [3]. The mechanistic and tissue-level work — SIRT1/STAT3 in murine DSS colitis, gene expression and mitochondrial function in human ulcer biopsies, epithelial regeneration in malnutrition enteropathy, and ZnC in oral mucosa — addresses the biology of repair rather than the validation of a marker panel [1][4][5][6]. The adjunct trial addresses treatment maintenance rather than marker performance [2]. No source in this evidence block provides a validated, clinically adopted marker set for mucosal healing, and the animal-model and in vitro components should be read as such.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing information or medical guidance, and nothing on this page should be used to self-treat a gastrointestinal or any other condition. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp